Fibrolamellar Carcinoma Overview
Learn About Fibrolamellar Carcinoma
- Fibrolamellar carcinoma
- Eosinophilic glassy cell hepatoma
- Eosinophilic hepatocellular carcinoma with lamellar fibrosis
- FHCC
- FL-HCC
- Fibrolamellar hepatocarcinoma
- Fibrolamellar hepatocellular carcinoma
- Fibrolamellar oncocytic hepatoma
- Hepatocellular carcinoma with increased stromal fibrosis
- Polygonal cell hepatocellular carcinoma with fibrous stroma
MD Anderson
Ahmed Kaseb is an Oncologist in Houston, Texas. Dr. Kaseb and is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Liver Cancer, Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Hepatectomy, and Liver Embolization.
Sanford Simon is a Family Medicine provider in Prospect, Kentucky. Dr. Simon and is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Liver Cancer, Angiosarcoma of the Liver, and HIV/AIDS.
Johns Hopkins University
Mark Yarchoan is an Oncologist in Columbia, Maryland. Dr. Yarchoan and is rated as an Elite provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.
Summary: The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in combination with anti-programmed cell death-ligand 1 immune checkpoint inhibition (ICI) by Atezolizumab (TecentriqTM) in patients with Fibrolamellar hepatocellular carcinoma (FL-HCC) or other cancer...
Summary: The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center